Host immunity and vaccine development against Dengue virus
Dengue is one of the most prevalent and influential mosquito-borne viral infections in the world. According to 1 modeling estimate, the World Health Organization indicated that the annual cases of dengue virus (DENV) infection are as high as 390 million, placing more than half of the global populati...
Main Authors: | Enhao Ma, Gong Cheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-03-01
|
Series: | Infectious Medicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2772431X2200003X |
Similar Items
-
Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
by: Adam T. Waickman, et al.
Published: (2019-07-01) -
Dengue Virus and Vaccines: How Can DNA Immunization Contribute to This Challenge?
by: Ada Maria Barcelos Alves, et al.
Published: (2021-04-01) -
Vaccines and immunization strategies for dengue prevention
by: Yang Liu, et al.
Published: (2016-01-01) -
Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 studyResearch in context
by: Alix Miauton, et al.
Published: (2024-01-01) -
Enhancement of Tetravalent Immune Responses to Highly Conserved Epitopes of a Dengue Peptide Vaccine Conjugated to Polystyrene Nanoparticles
by: Yanqi Chan, et al.
Published: (2020-07-01)